Hypermarcas (OTCMKTS:HYPMY - Get Free Report)'s stock price gapped down prior to trading on Thursday . The stock had previously closed at $5.02, but opened at $4.79. Hypermarcas shares last traded at $4.74, with a volume of 973 shares.
Hypermarcas Trading Down 7.5%
The stock has a 50 day moving average of $4.62 and a 200 day moving average of $3.79. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.26 and a quick ratio of 0.80. The firm has a market cap of $2.94 billion, a P/E ratio of 19.33 and a beta of 0.81.
Hypermarcas (OTCMKTS:HYPMY - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The company reported ($0.04) EPS for the quarter. The business had revenue of $184.34 million during the quarter. Hypermarcas had a return on equity of 6.95% and a net margin of 12.51%.
Hypermarcas Announces Dividend
The business also recently announced a dividend, which will be paid on Friday, January 8th. Stockholders of record on Tuesday, July 1st will be given a $0.0345 dividend. The ex-dividend date is Monday, June 30th. This represents a dividend yield of 2.81%. Hypermarcas's dividend payout ratio is 58.33%.
Hypermarcas Company Profile
(
Get Free Report)
Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Hypermarcas, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hypermarcas wasn't on the list.
While Hypermarcas currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
